Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigational Therapies for Moderate to Critical COVID-19
NCT04492501Phase 2Completed
- Sponsor
- UNICEF
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of remdesivir, tocilizumab, mesenchymal stem cell therapy (Hexun Biosciences), convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19), sponsored by UNICEF. Started Apr 2020; status: completed.
02
Drugs
remdesivirtocilizumabmesenchymal stem cell therapy (Hexun Biosciences)convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04492501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492501.